tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Paul Matteis, 167 are a BUY (66.27%), 85 are a HOLD (33.73%).
Analyst Paul Matteis, currently employed at STIFEL, carries an average stock price target met ratio of 54.8% that have a potential upside of 34.39% achieved within 207 days.
Paul Matteis’s has documented 517 price targets and ratings displayed on 36 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on BMRN, Biomarin Pharmaceutical at 17-Sep-2024.
Analyst best performing recommendations are on AVDL (AVADEL PHARMACEUTICALS PLC).
The best stock recommendation documented was for AVDL (AVADEL PHARMACEUTICALS PLC) at 5/26/2022. The price target of $2 was fulfilled within 1 day with a profit of $0.93 (86.92%) receiving and performance score of 869.16.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Hold
26 days ago
(10-Oct-2024)
11/14 (78.57%)
$9.98 (39.89%)
141
Buy
$23
$8.19 (55.30%)
$30
2 months 28 days ago
(08-Aug-2024)
0/3 (0%)
$7.28 (46.31%)
Buy
$27
$12.19 (82.31%)
$27
2 months 28 days ago
(08-Aug-2024)
8/21 (38.1%)
$11.28 (71.76%)
119
Buy
$20
$5.19 (35.04%)
$28
2 months 29 days ago
(07-Aug-2024)
16/21 (76.19%)
$4.83 (31.84%)
184
Buy
$28
$13.19 (89.06%)
$30
2 months 29 days ago
(07-Aug-2024)
0/3 (0%)
$12.83 (84.57%)
Which stock is Paul Matteis is most bullish on?
Which stock is Paul Matteis is most reserved on?
What Year was the first public recommendation made by Paul Matteis?
